Jpmorgan Chase & CO Neuro Pace Inc Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Neuro Pace Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 64,826 shares of NPCE stock, worth $689,748. This represents 0.0% of its overall portfolio holdings.

Number of Shares

64,826

Previous 11,997 440.35%

Holding current value

$689,748

Previous $83,000 773.49%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$5.9 - $11.93 $311,691 - $630,249	52,829 Added 440.35%	64,826 $725,000
Q3 2024 Dec 26, 2024	BUY	$6.65 - $8.46 $41,103 - $52,291	6,181 Added 106.28%	11,997 $83,000
Q3 2024 Nov 08, 2024	BUY	$6.65 - $8.46 $41,103 - $52,291	6,181 Added 106.28%	11,997 $83,000
Q2 2024 Dec 26, 2024	SELL	$6.38 - $15.33 $39,434 - $94,754	-6,181 Reduced 51.52%	5,816 $43,000
Q2 2024 Aug 12, 2024	SELL	$6.38 - $15.33 $167,787 - $403,163	-26,299 Reduced 81.89%	5,816 $43,000
Q1 2024 Dec 26, 2024	BUY	$9.78 - $17.5 $196,754 - $352,065	20,118 Added 167.69%	32,115 $423,000
Q1 2024 May 10, 2024	BUY	$9.78 - $17.5 $202,983 - $363,212	20,755 Added 182.7%	32,115 $423,000
Q4 2023 Dec 26, 2024	SELL	$5.9 - $10.31 $3,758 - $6,567	-637 Reduced 5.31%	11,360 $117,000
Q4 2023 Feb 12, 2024	BUY	$5.9 - $10.31 $67,024 - $117,121	11,360 New	11,360 $117,000
Q2 2022 Aug 11, 2022	SELL	$4.95 - $8.7 $16,483 - $28,970	-3,330 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$7.06 - $11.57 $11,451 - $18,766	-1,622 Reduced 32.75%	3,330 $27,000
Q4 2021 Feb 10, 2022	BUY	$8.63 - $17.36 $19,659 - $39,546	2,278 Added 85.19%	4,952 $50,000
Q3 2021 Nov 12, 2021	BUY	$15.85 - $25.07 $42,382 - $67,037	2,674 New	2,674 $42,000

Others Institutions Holding NPCE

# of Institutions

Shares Held

21.7M

Call Options Held

23.2K

Put Options Held

800

View Full List

About NeuroPace Inc

Ticker NPCE
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 24,846,900
Market Cap $264M
Description
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...

More about NPCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Neuro Pace Inc Transaction History